| Literature DB >> 28901389 |
Veronika Živicová1, Lukáš Lacina1, Rosana Mateu1, Karel Smetana1, Radana Kavková1, Eliška Drobná Krejčí1, Miloš Grim1, Alena Kvasilová1, Jiří Borský2, Hynek Strnad3, Miluše Hradilová3, Jana Šáchová3, Michal Kolář3, Barbora Dvořánková1.
Abstract
The nonsyndromic cleft is one of the most frequent congenital defects in humans. Clinical data demonstrated improved and almost scarless neonatal healing of reparative surgery. Based on our previous results on crosstalk between neonatal fibroblasts and adult keratinocytes, the present study focused on characterization of fibroblasts prepared from cleft lip tissue samples of neonates and older children, and compared them with samples isolated from normal adult skin (face and breast) and scars. Although subtle variances in expression profiles of children and neonates were observed, the two groups differed significantly from adult cells. Compared with adult cells, differences were observed in nestin and smooth muscle actin (SMA) expression at the protein and transcript level. Furthermore, fibroblast to myofibroblast differentiation drives effective wound healing and is largely regulated by the cytokine, transforming growth factor-β1 (TGF-β1). Dysregulation of the TGF-β signalling pathway, including low expression of the TGF-β receptor II, may contribute to reducing scarring in neonates. Fibroblasts of facial origin also exhibited age independent differences from the cells prepared from the breast, reflecting the origin of the facial cells from neural crest-based ectomesenchyme.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28901389 PMCID: PMC5627884 DOI: 10.3892/ijmm.2017.3128
Source DB: PubMed Journal: Int J Mol Med ISSN: 1107-3756 Impact factor: 4.101
Antibodies used for immunohistochemical, immunocytochemical and western blot analysis.
| Primary antibody | Supplier (location) | Secondary antibody/fluorochrome | Supplier (location) |
|---|---|---|---|
| Merck KGaA (Darmstadt, Germany) | Goat anti-mouse/TRITC 115-025-044; 1:30 | Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA, USA) | |
| Sigma-Aldrich (Merck KGaA; Darmstadt, Germany) | Swine anti-rabbit/FITC F0205; 1:30 | Dako (Agilent Technologies, Inc., Santa Clara, CA, USA) | |
| Dako (Agilent Technologies, Inc., Santa Clara, CA, USA) | Goat anti-mouse/TRITC T5393; 1:30 | Sigma-Aldrich (Merck KGaA; Darmstadt, Germany) | |
| R&D Systems, Inc. (Minneapolis, MN, USA) | Donkey anti-goat/TRITC Sc-2094; 1:200 | Santa Cruz Biotechnology, Inc. (Dallas, TX, USA) | |
| Melan A/M | Invitrogen (Thermo Fisher Scientific, Inc., Waltham, MA, USA) | Goat anti-mouse/TRITC 115-025-044; 1:30 | Sigma-Aldrich (Merck KGaA; Darmstadt, Germany) |
| Abcam (Cambridge, UK) | Swine anti-rabbit/FITC F0205; 1:30 | Dako (Agilent Technologies, Inc., Santa Clara, CA, USA) | |
| Sigma-Aldrich (Merck KGaA; Darmstadt, Germany) | Goat anti-mouse/horseradish peroxidase Sc-516102; 1:2,000 | Santa Cruz Biotechnology, Inc. (Dallas, TX, USA) |
TRITC, tetramethylrhodamine; FITC, fluorescein isothiocyanate.
Figure 1Comparison of nestin expression in adult, child and neonatal fibroblasts. Immunocytochemical detection of nestin-positive cells in (A) adults and (B) neonates, and (C) their percentage quantification in all studied fibroblasts. (D) Data from expression profiling. Potential statistical significance between tested types of fibroblasts was marked by use of line segments connecting tested cell types; *p<0.05 indicates a statistically significant differences; **p<0.05 indicates a statistically significant difference and a minimum of a 2-fold (δ>2) change. Vim, vimentin; Nest, nestin; n.s., not significant.
Figure 2Expression of nestin in dermis samples obtained from (A) a child and (B) a neonate. Red signal detects fibroblasts positive for nestin. The nuclei of all cells are blue because they were counterstained with 4′,6-diamidino-2-phenylindole (DAPI).
Figure 3Detection of Nanog and Oct4 was performed by double staining immunocychemistry at single-cell level in neonatal fibroblasts that were negative for smooth muscle actin. Visualization of Nanog in (A) red tetramethylrhodamine channel, (B) Oct4 in green fluorescein isothiocyanate channel and (C) merged figure. (D and E) Data from expression profiles, where no significant differences were identified. Oct4, octamer-binding transcription factor 4.
Figure 4Expression levels of SMA in (A) adult breast and (B) neonatal fibroblasts as quantified by immunohistochemistry and (C) WB analysis of representative neonatal and adult fibroblasts. (D) Proportion of SMA-positive cells detected by immunocytochemistry. (E) ACTA2 and (F) ACTG2 gene activities are also demonstrated. Potential statistical significance between tested types of fibroblasts was marked by use of line segments connecting tested cell types; **p<0.05 indicates a statistically significant difference and a minimum of a 2-fold (δ>2) change. SMA, smooth muscle actin; WB, western blotting; ACTA2, actin α2, smooth muscle, aorta; ACTG2, actin γ2, smooth muscle, enteric; αTUB, α tubulin; mRNA, messenger RNA.
Figure 5Production of (A) IL-6 and (B) IL-8 to cultivation media measured by enzyme-linked immunosorbent assay (ELISA) compared with detection of (C) IL-6 and (D) IL-8 gene activity. Potential statistical significance between tested types of fibroblasts was marked by use of line segments connecting tested cell types; *p<0.05 and **p<0.05 indicates a statistically significant difference and a minimum of a 2-fold (δ>2) change. IL, interleukin.
Figure 6Heat map demonstrating differences in the expression profiles of all of the investigated types of fibroblast.
Figure 7Heat map demonstrating the expression of HOX genes in all of the evaluated types of fibroblast.
Figure 8Detection of (A) TGF-β2, (B) TGF-β3, (C) TGF-βR2 receptor, (D) TGF-α and (E) SMAD3 gene activity in all of the tested types of fibroblast. Potential statistical significance between tested types of fibroblasts was marked by use of line segments connecting tested cell types; *p<0.05 and **p<0.05 indicates a statistically significant difference and a minimum of a 2-fold (δ>2) change. TGF-β2, transforming growth factor-β2; TGF-βR2, transforming growth factor-β receptor 2; TGF-α, transforming growth factor-α; SMAD3, SMAD family member 3.
Figure 9Kyoto Encyclopedia of Genes and Genomes and TGF-β signaling pathway with changes between adult facial fibroblasts and neonate fibroblasts denoted by color code. TGF-β family member binds to the type II receptor and recruits type I, whereby type II receptor phosphorylates and activates type I. The type I receptor, in turn, phosphorylates receptor-activated Smads (R-Smads: Smad1, Smad2, Smad3, Smad5 and Smad8). Once phosphorylated, R-Smads associate with the co-mediator smad, smad4 and the heteromeric complex then translocates into the nucleus. In the nucleus, smad complexes activate specific genes via cooperative interactions with other DNA-binding and coactivator (or co-repressor) proteins. TGF-β, transforming growth factor-β; Smad, SMAD family member.
Figure 10Effect of TGF-β3 and TGF-β inhibitor on growth kinetics of neonate, child, and adult fibroblasts measured using IncuCyte. The time dependence of cell confluency is represented. The shadows determine the spread of the technical replicates. Note the insensitivity of neonatal cells to inhibition. TGF-β, transforming growth factor-β; DMEM, Dulbecco's modified Eagle's medium.